CellFE, Inc.

CellFE is developing a mechano-poration method to transfect nucleic acids and other particles into cells at a lower cost and with less damage to the recipient cell than alternative methods. Elm Street Ventures invested in the seed round alongside venture funds Dynamk, Cota, and Embark. ESV Managing Partner Chris McLeod is a board observer.